Wang, S.-H.; Yeh, C.-H.; Wu, C.-W.; Hsu, C.-Y.; Tsai, E.-M.; Hung, C.-M.; Wang, Y.-W.; Hsieh, T.-H.
PFDN4 as a Prognostic Marker Was Associated with Chemotherapy Resistance through CREBP1/AURKA Pathway in Triple-Negative Breast Cancer. Int. J. Mol. Sci. 2024, 25, 3906.
https://doi.org/10.3390/ijms25073906
AMA Style
Wang S-H, Yeh C-H, Wu C-W, Hsu C-Y, Tsai E-M, Hung C-M, Wang Y-W, Hsieh T-H.
PFDN4 as a Prognostic Marker Was Associated with Chemotherapy Resistance through CREBP1/AURKA Pathway in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 2024; 25(7):3906.
https://doi.org/10.3390/ijms25073906
Chicago/Turabian Style
Wang, Shih-Ho, Cheng-Hsi Yeh, Chia-Wei Wu, Chia-Yi Hsu, Eing-Mei Tsai, Chao-Ming Hung, Yi-Wen Wang, and Tsung-Hua Hsieh.
2024. "PFDN4 as a Prognostic Marker Was Associated with Chemotherapy Resistance through CREBP1/AURKA Pathway in Triple-Negative Breast Cancer" International Journal of Molecular Sciences 25, no. 7: 3906.
https://doi.org/10.3390/ijms25073906
APA Style
Wang, S.-H., Yeh, C.-H., Wu, C.-W., Hsu, C.-Y., Tsai, E.-M., Hung, C.-M., Wang, Y.-W., & Hsieh, T.-H.
(2024). PFDN4 as a Prognostic Marker Was Associated with Chemotherapy Resistance through CREBP1/AURKA Pathway in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 25(7), 3906.
https://doi.org/10.3390/ijms25073906
